Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

Vera Therapeutics (VERA) will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.

Rhea-AI Summary

Vera Therapeutics (VERA) will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.

The chat begins at 11:30 AM ET. Management will also hold one-on-one investor meetings at the Boston conference, which runs November 9–11, 2026. A webcast replay will be available for 90 days through the News & Events section at ir.veratx.com.

Argus 15 min delay 15 alerts

+2.42% vs previous close $31.73 last price 1.9x rel. volume Open Argus

Details

Market Reaction – VERA

$28.00 – $32.78 Day Range

$2.29B Mkt Cap at Last Price

On Nov 2, the day this news came out, the latest delayed price for VERA is 2.42% above the previous close. Our momentum scanner has recorded 15 alerts for this stock so far that day. The latest delayed price is $31.73. Relative volume is above average at 1.9x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

b-cell activating factor, a proliferation-inducing ligand, autoantibodies

3 terms

b-cell activating factor medical

"a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor"

B‑cell activating factor is a naturally occurring protein that helps B cells — the immune cells that make antibodies — grow, survive and produce antibodies; think of it like a fertilizer for a specific plant in the immune system garden. It matters to investors because drugs or diagnostic tests that block or measure this protein are used to treat or track autoimmune diseases and some cancers, so clinical data or regulatory news about BAFF-targeting approaches can materially affect biotech and pharmaceutical valuations.

a proliferation-inducing ligand medical

"a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor"

A proliferation‑inducing ligand (APRIL) is a small signaling protein in the tumor necrosis factor (TNF) superfamily that binds receptors on B cells and related immune cells to promote their survival, growth and antibody-producing differentiation. It is produced by various immune and stromal cells, signals mainly through the receptors BCMA and TACI (and via interactions with heparan sulfate proteoglycans), and is implicated in normal plasma‑cell maintenance as well as in autoimmune disorders and B‑cell cancers where its excess can support pathological cell survival.

autoantibodies medical

"where the reduction of autoantibodies through inhibition of BAFF and APRIL"

Autoantibodies are proteins made by the immune system that mistakenly target a person’s own tissues, like friendly fire where soldiers attack their own team. They matter to investors because their presence influences diagnosis, disease progression, and patient safety, which can affect demand for drugs, diagnostic tests, trial outcomes, regulatory decisions, and potential liabilities in healthcare-related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, which is taking place in Boston, MA from November 9-11, 2026. The management team will also participate in one-on-one investor meetings.

Fireside Chat Details:
Date: Tuesday, November 10, 2026
Time: 11:30 AM ET
Webcast: https://event.summitcast.com/view/oVDtKqmPn2tPc7VV7WsLAC/VAEZkbjVkcydrQYaGzVnEF

A replay of the event will be available for 90 days and can be accessed by visiting the News & Events section of the Company’s website at ir.veratx.com.

About Vera Therapeutics

Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA™ (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

Forward-looking Statements

Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential for TRUTAKNA to be a disease-modifying therapy; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks related to commercial launch, market acceptance, and payer coverage, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com